Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
The company will be managing orders and warehouse operations for Little's, Lacto-calamine, Tri-activ, I-feel, Ourdaily, and Sloan's through the Unicommerce platform
The company recently received CEP certificate approval for Losartan Potassium by EDQM
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Subscribe To Our Newsletter & Stay Updated